Amarin - The Science Of Lipid Therapy (Seite 36)
eröffnet am 03.01.14 20:10:32 von
neuester Beitrag 04.04.24 15:47:54 von
neuester Beitrag 04.04.24 15:47:54 von
Beiträge: 1.840
ID: 1.190.027
ID: 1.190.027
Aufrufe heute: 2
Gesamt: 156.426
Gesamt: 156.426
Aktive User: 0
ISIN: US0231112063 · WKN: A0NBNG · Symbol: EH3A
0,8899
USD
+2,29 %
+0,0199 USD
Letzter Kurs 21:16:52 Nasdaq
Neuigkeiten
06.05.24 · globenewswire  |
01.05.24 · globenewswire |
24.04.24 · globenewswire |
22.04.24 · globenewswire |
15.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 3,0000 | +42,18 | |
| 1,3000 | +30,00 | |
| 2,0600 | +24,85 | |
| 0,9600 | +18,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,9000 | -10,96 | |
| 20,360 | -11,48 | |
| 1,2200 | -16,44 | |
| 23,700 | -19,52 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 67.721.593 von bernie55 am 07.04.21 00:16:26Da freut man sich doch schon über solche News , die zumindest perspektivisch glücklich stimmen. 
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler.
Piper Sandler analyst Yasmeen Rahimi is "very impressed" with Amarin's European Union commercial game plan. With 150 sales reps already hired and ready by mid Q2, supported by plans for digital and medical education, "all eyes are fixed" on Vazkepa's initial launch in Germany in Q3, Rahimi tells investors in a research note.
The analyst believes Amarin is "one step closer to capturing a multi-billion dollar EU opportunity." The company has built a "solid commercial strategy" ahead of the European launch focused on growing physician awareness, beginning with Germany, says Rahimi.
The analyst keeps an Overweight rating on the shares with a $19 price target.
Read more at:
https://thefly.com/n.php?id=3277954
Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler.
Piper Sandler analyst Yasmeen Rahimi is "very impressed" with Amarin's European Union commercial game plan. With 150 sales reps already hired and ready by mid Q2, supported by plans for digital and medical education, "all eyes are fixed" on Vazkepa's initial launch in Germany in Q3, Rahimi tells investors in a research note.
The analyst believes Amarin is "one step closer to capturing a multi-billion dollar EU opportunity." The company has built a "solid commercial strategy" ahead of the European launch focused on growing physician awareness, beginning with Germany, says Rahimi.
The analyst keeps an Overweight rating on the shares with a $19 price target.
Read more at:
https://thefly.com/n.php?id=3277954
Antwort auf Beitrag Nr.: 67.717.618 von lobberland am 06.04.21 17:56:30Der Kurs wird - bis zum geht nicht mehr - unten gehalten , da kann an Super-News aktuell leider kommen was will. 😢 😴
Antwort auf Beitrag Nr.: 67.713.082 von bernie55 am 06.04.21 12:48:22Wenn man bei der Newslsge den Kurs betrachtet, könnte man meinen hier wird mit Valium gehandelt 😴😴😴
Antwort auf Beitrag Nr.: 67.687.444 von bernie55 am 01.04.21 23:17:20
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
April 06, 2021 06:05 ET
Summary:
- Erstattungsdossiers für die ersten 10 Länder werden in den kommenden Monaten eingereicht
- Einstellung von 150 Mitarbeitern, die bis Mitte des zweiten Quartals 2021 eingesetzt werden sollen, ergänzt durch digitale Outreach- und medizinische Aufklärungsprogramme mit anfänglicher oberster Priorität in Deutschland
- Markteinführung von VAZKEPA in Deutschland für Q3 2021 geplant
https://www.globenewswire.com/news-release/2021/04/06/220478…
Zitat von bernie55: Nach EU - Approval ist die Amarin-Webseite in Deutschland bereits online
AMARIN und sein Engagement für eine bessere kardiovaskuläre Gesundheit
Erfahren Sie mehr unter https://amarincorp.de/
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
April 06, 2021 06:05 ET
Summary:
- Erstattungsdossiers für die ersten 10 Länder werden in den kommenden Monaten eingereicht
- Einstellung von 150 Mitarbeitern, die bis Mitte des zweiten Quartals 2021 eingesetzt werden sollen, ergänzt durch digitale Outreach- und medizinische Aufklärungsprogramme mit anfänglicher oberster Priorität in Deutschland
- Markteinführung von VAZKEPA in Deutschland für Q3 2021 geplant
https://www.globenewswire.com/news-release/2021/04/06/220478…
20 APRIL 2021
10:00AM – 10:20AM (CET)
From the ground-up. How AMARIN Corp built its EU commercial organization with a data-and-digital-focus to deliver in a crowded market
The vision. How Amarin Corp identified its key principles for a 21st century commercial pharma organization that adds-value with each customer touchpoint.
Hear how Amarin Corp developed it’s Go-To-Market approach with fully comprehensive digital-customer experience, whilst also ensuring they are equipped for field activities when available.
Why you need to create a dynamic model that can transform as data and digital capabilities evolve
https://reutersevents.com/events/customer/conference-agenda.…
Trading Spotlight
Low HDL and high triglycerides predict COVID-19 severity
Neue Studie ( Artikel auf Nature) zeigt :
Niedriges HDL und hohe Triglyceride sagen den Schweregrad von COVID-19 voraus - somit ein sehr guter Ansatzpunkt zur Verabreichung von VASCEPA.
https://www.nature.com/articles/s41598-021-86747-5#Sec4
Neue Studie ( Artikel auf Nature) zeigt :
Niedriges HDL und hohe Triglyceride sagen den Schweregrad von COVID-19 voraus - somit ein sehr guter Ansatzpunkt zur Verabreichung von VASCEPA.
https://www.nature.com/articles/s41598-021-86747-5#Sec4
👍Nach EU - Approval ist die Amarin-Webseite in Deutschland bereits online👍
AMARIN und sein Engagement für eine bessere kardiovaskuläre Gesundheit
Erfahren Sie mehr unter https://amarincorp.de/
AMARIN und sein Engagement für eine bessere kardiovaskuläre Gesundheit
Erfahren Sie mehr unter https://amarincorp.de/
2 Great Stocks Under $10 per Share
Amarin and Accelerate Diagnostics are healthcare companies with significant upside.
Taylor Carmichael
(TMFSaintCroix)
Apr 1, 2021 at 6:22AM
Author Bio
Finding amazing stocks under $10 can be tricky. Last year, I hit the jackpot with Novavax (NASDAQ:NVAX), buying shares at $4, and then riding the stock all the way up to $300 a share earlier this year.
Can I replicate my Novavax success? That would be nice. Here are two stocks under $10 that might go a lot higher: Amarin (NASDAQ:AMRN) and Accelerate Diagnostics (NASDAQ:AXDX). Here's why I think these two biotech stocks have a good shot at outperforming the market over the next several years.
Female pharmacist in a white coat holds a medicine bottle while leaning against a wall of medicine drawers and files.
Image source: Getty Images
1. Amarin -- $6 per share
This Irish biotech is my favorite value play right now. The company has an amazing drug, Vascepa, which reduces the risk of major adverse cardiovascular events by 25% in people who are on statin therapy. This is big news, as it suggests a new understanding of heart disease, the No. 1 killer of humans -- namely, that it's not enough to control cholesterol with statins. Vascepa reduces triglycerides (a type of fat in your blood). According to a Harvard study from 2018, by reducing triglycerides, Vascepa succeeded in reducing heart attacks, strokes, and deaths.
Why is the stock so cheap? I see two reasons. Number one is the fact that the COVID-19 lockdown has hampered sales growth. Doctors have to be informed about new medical breakthroughs, but that's hard to do in the midst of a lockdown, during which it has been hard to reach doctors. Despite that difficulty, Amarin increased revenue by 43% in 2020. I expect that rate to increase dramatically when the COVID-19 lockdown is over.
The main reason the stock is cheap, however, is that a couple of Amarin's patents were invalidated by a trial judge last year. That's opened the door to generic companies offering a version of Vascepa in the U.S., and cast a cloud over the company's growth story. All that doubt has been baked into the share price, and then some.
Nonetheless, I expect Vascepa sales to spike in the future. The market opportunity is massive, as an estimated 80 million people in Europe alone have cardiovascular disease. Amarin's patents in the rest of the world remain intact, and the European Commission is now allowing Amarin to market the drug to reduce the risk of cardiovascular events. And the invalidated patents in the U.S. only allow competition in the market to reduce triglycerides, not in the market to improve heart health. In short, Amarin has an approved drug that will save lives, a huge market opportunity, a strong competitive moat, and a price-to-sales (P/S) ratio of 3. For those reasons, I'm bullish.
2. Accelerate Diagnostics -- $8 per share
What is a common reason people die in hospitals? They get an infection. When a bacteria invades your body, your immune system fights back, creating inflammation. This fight might lead to sepsis, which can cause tissue damage, organ failure, and unfortunately, death.
According to a study published in The Lancet, 20% of people who die worldwide actually died from sepsis. 270,000 people in the U.S. perish as a result of the disease every year, costing the U.S. healthcare system $68 billion annually. Up to 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.
The key issue confounding doctors is identifying which bacteria has infected the patient, and solving that mystery quickly. Once a patient has sepsis, without effective treatment, the odds of survival decrease by 7.6% every hour. Effective diagnosis is no good if it's too late to save the patient.
That's where Accelerate Diagnostics comes in. The company's medical device, the Accelerate Pheno, identifies the bacteria and the optimal therapy in under 16 hours. Conventional machines take 42 to 69 hours.
That's the ballgame right there. The faster the diagnosis, the more likely it is that you defeat sepsis. What's particularly nice for investors is that Accelerate has the classic razor-and-blades model that made Intuitive Surgical such an amazing investment. Placing the device in a hospital is just the first step. After the Pheno is installed, Accelerate will get recurring revenue from all the hospitals that use the device.
Sales of the Pheno have been escalating dramatically. The company reports that 268 systems have been placed in hospitals, with a backlog of 133. That leaves a vast market opportunity, with 6,000 hospitals in the U.S., and 160,000 hospitals worldwide.
Year Number of Pheno Devices Placed in Hospitals
2017 7
2018 54
2019 164
2020 268
Data source: Accelerate Diagnostics Investor Presentation
COVID-19 threw a wrench at the company last year, and in the second quarter Accelerate only placed four devices in hospitals. In the fourth quarter, however, 45 new devices were installed. This escalating demand, despite the pandemic, is a reason for investors to be bullish for 2021.
While Accelerate is not cheap, trading at 42 times sales, the upside is substantial. Both Accelerate and Amarin are going after massive market opportunities. Amarin has the added benefit of being really cheap right now. If either healthcare company succeeds, these stocks will be worth many multiples of where they are now.
Should you invest $1,000 in Amarin Corporation plc right now?
Before you consider Amarin Corporation plc, you'll want to hear this.
Investing legends and Motley Fool Co-founders David and Tom Gardner just revealed what they believe are the 10 best stocks for investors to buy right now... and Amarin Corporation plc wasn't one of them.
The online investing service they've run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.
Amarin and Accelerate Diagnostics are healthcare companies with significant upside.
Taylor Carmichael
(TMFSaintCroix)
Apr 1, 2021 at 6:22AM
Author Bio
Finding amazing stocks under $10 can be tricky. Last year, I hit the jackpot with Novavax (NASDAQ:NVAX), buying shares at $4, and then riding the stock all the way up to $300 a share earlier this year.
Can I replicate my Novavax success? That would be nice. Here are two stocks under $10 that might go a lot higher: Amarin (NASDAQ:AMRN) and Accelerate Diagnostics (NASDAQ:AXDX). Here's why I think these two biotech stocks have a good shot at outperforming the market over the next several years.
Female pharmacist in a white coat holds a medicine bottle while leaning against a wall of medicine drawers and files.
Image source: Getty Images
1. Amarin -- $6 per share
This Irish biotech is my favorite value play right now. The company has an amazing drug, Vascepa, which reduces the risk of major adverse cardiovascular events by 25% in people who are on statin therapy. This is big news, as it suggests a new understanding of heart disease, the No. 1 killer of humans -- namely, that it's not enough to control cholesterol with statins. Vascepa reduces triglycerides (a type of fat in your blood). According to a Harvard study from 2018, by reducing triglycerides, Vascepa succeeded in reducing heart attacks, strokes, and deaths.
Why is the stock so cheap? I see two reasons. Number one is the fact that the COVID-19 lockdown has hampered sales growth. Doctors have to be informed about new medical breakthroughs, but that's hard to do in the midst of a lockdown, during which it has been hard to reach doctors. Despite that difficulty, Amarin increased revenue by 43% in 2020. I expect that rate to increase dramatically when the COVID-19 lockdown is over.
The main reason the stock is cheap, however, is that a couple of Amarin's patents were invalidated by a trial judge last year. That's opened the door to generic companies offering a version of Vascepa in the U.S., and cast a cloud over the company's growth story. All that doubt has been baked into the share price, and then some.
Nonetheless, I expect Vascepa sales to spike in the future. The market opportunity is massive, as an estimated 80 million people in Europe alone have cardiovascular disease. Amarin's patents in the rest of the world remain intact, and the European Commission is now allowing Amarin to market the drug to reduce the risk of cardiovascular events. And the invalidated patents in the U.S. only allow competition in the market to reduce triglycerides, not in the market to improve heart health. In short, Amarin has an approved drug that will save lives, a huge market opportunity, a strong competitive moat, and a price-to-sales (P/S) ratio of 3. For those reasons, I'm bullish.
2. Accelerate Diagnostics -- $8 per share
What is a common reason people die in hospitals? They get an infection. When a bacteria invades your body, your immune system fights back, creating inflammation. This fight might lead to sepsis, which can cause tissue damage, organ failure, and unfortunately, death.
According to a study published in The Lancet, 20% of people who die worldwide actually died from sepsis. 270,000 people in the U.S. perish as a result of the disease every year, costing the U.S. healthcare system $68 billion annually. Up to 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.
The key issue confounding doctors is identifying which bacteria has infected the patient, and solving that mystery quickly. Once a patient has sepsis, without effective treatment, the odds of survival decrease by 7.6% every hour. Effective diagnosis is no good if it's too late to save the patient.
That's where Accelerate Diagnostics comes in. The company's medical device, the Accelerate Pheno, identifies the bacteria and the optimal therapy in under 16 hours. Conventional machines take 42 to 69 hours.
That's the ballgame right there. The faster the diagnosis, the more likely it is that you defeat sepsis. What's particularly nice for investors is that Accelerate has the classic razor-and-blades model that made Intuitive Surgical such an amazing investment. Placing the device in a hospital is just the first step. After the Pheno is installed, Accelerate will get recurring revenue from all the hospitals that use the device.
Sales of the Pheno have been escalating dramatically. The company reports that 268 systems have been placed in hospitals, with a backlog of 133. That leaves a vast market opportunity, with 6,000 hospitals in the U.S., and 160,000 hospitals worldwide.
Year Number of Pheno Devices Placed in Hospitals
2017 7
2018 54
2019 164
2020 268
Data source: Accelerate Diagnostics Investor Presentation
COVID-19 threw a wrench at the company last year, and in the second quarter Accelerate only placed four devices in hospitals. In the fourth quarter, however, 45 new devices were installed. This escalating demand, despite the pandemic, is a reason for investors to be bullish for 2021.
While Accelerate is not cheap, trading at 42 times sales, the upside is substantial. Both Accelerate and Amarin are going after massive market opportunities. Amarin has the added benefit of being really cheap right now. If either healthcare company succeeds, these stocks will be worth many multiples of where they are now.
Should you invest $1,000 in Amarin Corporation plc right now?
Before you consider Amarin Corporation plc, you'll want to hear this.
Investing legends and Motley Fool Co-founders David and Tom Gardner just revealed what they believe are the 10 best stocks for investors to buy right now... and Amarin Corporation plc wasn't one of them.
The online investing service they've run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.
Antwort auf Beitrag Nr.: 67.662.169 von asthmamoah am 31.03.21 09:00:34Not worth mentioning 😉
Antwort auf Beitrag Nr.: 67.660.645 von bernie55 am 31.03.21 01:12:14Wer Lesen kann, ist klar im Vorteil. 😅 Danke Dir, Bernie
Durchsuchen
Amarin - The Science Of Lipid Therapy
